Phase III MIRASOL (GOG 3045/ENGOT-ov55) study: Initial report of mirvetuximab soravtansine vs. investigator's choice of chemotherapy in platinum-resistant, advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor-alpha expression.Kathleen N. Moore, Toon Van Gorp, Sandro Pignata et al.|Journal of Clinical Oncology|2023Cited by 53
Trabectedin (T) in relapsed advanced ovarian cancer (ROC): A pooled analysis of three phase II studiesScott McMeekin, C. Sessa, Josep M. del Campo et al.|Journal of Clinical Oncology|2007Cited by 16